Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: The c.1617del variant of TMEM260 is identified as the most frequent single gene determinant for Japanese patients with a specific type of congenital heart disease.
Inoue T, Takase R, Uchida K, Kodo K, Suda K, Watanabe Y, Yoshiura KI, Kunimatsu M, Ishizaki R, Azuma K, Inai K, Muneuchi J, Furutani Y, Akagawa H, Yamagishi H. Inoue T, et al. Among authors: azuma k. J Hum Genet. 2024 May;69(5):223. doi: 10.1038/s10038-024-01238-5. J Hum Genet. 2024. PMID: 38459226 No abstract available.
The c.1617del variant of TMEM260 is identified as the most frequent single gene determinant for Japanese patients with a specific type of congenital heart disease.
Inoue T, Takase R, Uchida K, Kodo K, Suda K, Watanabe Y, Yoshiura KI, Kunimatsu M, Ishizaki R, Azuma K, Inai K, Muneuchi J, Furutani Y, Akagawa H, Yamagishi H. Inoue T, et al. Among authors: azuma k. J Hum Genet. 2024 May;69(5):215-222. doi: 10.1038/s10038-024-01225-w. Epub 2024 Feb 26. J Hum Genet. 2024. PMID: 38409496 Free PMC article.
Whole-exome sequencing reveals the genetic causes and modifiers of moyamoya syndrome.
Nakamura A, Nomura S, Hara S, Thamamongood T, Maehara T, Nariai T, Khairullah S, Tan KS, Azuma K, Chida-Nagai A, Furutani Y, Hori T, Yamaguchi K, Kawamata T, Roder C, Akagawa H. Nakamura A, et al. Among authors: azuma k. Sci Rep. 2024 Oct 4;14(1):22720. doi: 10.1038/s41598-024-72043-5. Sci Rep. 2024. PMID: 39367156 Free PMC article.
Difference in Clinical Phenotype, Mutation Position, and Structural Change of RNF213 Rare Variants Between Pediatric and Adult Japanese Patients with Moyamoya Disease.
Nomura S, Akagawa H, Yamaguchi K, Azuma K, Nakamura A, Fukui A, Matsuzawa F, Aihara Y, Ishikawa T, Moteki Y, Chiba K, Hashimoto K, Morita S, Ishiguro T, Okada Y, Vetiska S, Andrade-Barazarte H, Radovanovic I, Kawashima A, Kawamata T. Nomura S, et al. Among authors: azuma k. Transl Stroke Res. 2024 Dec;15(6):1142-1153. doi: 10.1007/s12975-023-01194-w. Epub 2023 Sep 28. Transl Stroke Res. 2024. PMID: 37768541
A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
Akamatsu H, Sakata S, Azuma K, Yoshioka H, Uemura T, Tsuchiya-Kawano Y, Esumi S, Kurosaki T, Sato Y, Sakamoto T, Ninomiya K, Toyozawa R, Yoneshima Y, Shukuya T, Kozuki T, Watanabe K, Daga H, Kato T, Takahashi T, Osuga M, Koh Y, Morita S, Yamamoto N. Akamatsu H, et al. Among authors: azuma k. J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007-3. doi: 10.1016/j.jtho.2025.01.006. Online ahead of print. J Thorac Oncol. 2025. PMID: 39828218 Free article.
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG). Fukui T, et al. Among authors: azuma k. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755169
Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.
Xiang H, Kasajima R, Azuma K, Tagami T, Hagiwara A, Nakahara Y, Saito H, Igarashi Y, Wei F, Ban T, Yoshihara M, Nakamura Y, Sato S, Koizume S, Tamura T, Sasada T, Miyagi Y. Xiang H, et al. Among authors: azuma k. Front Immunol. 2024 Dec 13;15:1361992. doi: 10.3389/fimmu.2024.1361992. eCollection 2024. Front Immunol. 2024. PMID: 39735553 Free PMC article.
1,072 results